PriceTargets.com logo

Lumos Pharma - LUMO Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$4.34 As of 12/12/2024 01:00 AM ET
+0 (0.00%)
Get New Lumos Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LUMO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LUMO

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Lumos Pharma in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $4.34.

This chart shows the closing price for LUMO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Lumos Pharma. This rating changed within the last month from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 1 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 1 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 1 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 1 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/8/2024HC WainwrightReiterated RatingNeutral ➝ Neutral$4.25 ➝ $4.25
10/24/2024HC WainwrightReiterated RatingBuy ➝ Neutral$28.00 ➝ $4.25
9/27/2024HC WainwrightReiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
9/24/2024EF Hutton Acquisition Co. IUpgradeStrong-Buy
8/2/2024OppenheimerLower TargetOutperform ➝ Outperform$16.00 ➝ $13.00
3/20/2024HC WainwrightReiterated RatingBuy ➝ Buy$28.00
12/11/2023OppenheimerLower TargetOutperform ➝ Outperform$17.00 ➝ $16.00
12/7/2023HC WainwrightReiterated RatingBuy ➝ Buy$28.00
9/6/2023HC WainwrightReiterated RatingBuy ➝ Buy$28.00
8/22/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$10.00
8/15/2023Cantor FitzgeraldLower TargetOverweight ➝ Overweight$14.00 ➝ $10.00
8/10/2023OppenheimerLower TargetOutperform ➝ Outperform$18.00 ➝ $17.00
8/10/2023HC WainwrightReiterated RatingBuy ➝ Buy$28.00
7/24/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$14.00
3/6/2023HC WainwrightReiterated RatingBuy$28.00
12/8/2022Jefferies Financial GroupDowngradeBuy ➝ Hold
11/17/2022OppenheimerLower Target$18.00
11/15/2022Cantor FitzgeraldReiterated RatingOverweight
11/14/2022Jefferies Financial GroupDowngradeBuy ➝ Hold$7.00
8/9/2022Roth CapitalReiterated RatingBuy
7/19/2022OppenheimerInitiated CoverageOutperform$20.00
11/4/2021HC WainwrightBoost TargetBuy$27.00 ➝ $28.00
8/6/2021JonestradingReiterated RatingBuy$25.00
7/22/2021Roth CapitalLower TargetBuy$51.00 ➝ $35.00
7/21/2021HC WainwrightLower TargetBuy$34.00 ➝ $27.00
4/13/2021JonestradingInitiated CoverageBuy$34.00
3/11/2021Stifel NicolausUpgradeHold ➝ Buy$4.00 ➝ $24.00
(Data available from 12/5/2020 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/9/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/8/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/8/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/7/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/6/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/6/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/5/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/5/2025

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Lumos Pharma logo
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company has a clinical collaboration with Massachusetts General Hospital to evaluate oral LUM-201 in nonalcoholic fatty liver disease. Lumos Pharma, Inc. is headquartered in Austin, Texas.
Read More

Today's Range

Now: $4.34
Low: $4.34
High: $4.34

50 Day Range

MA: $4.34
Low: $4.30
High: $4.41

52 Week Range

Now: $4.34
Low: $1.46
High: $4.58

Volume

N/A

Average Volume

100,335 shs

Market Capitalization

$37.54 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.74

Frequently Asked Questions

What sell-side analysts currently cover shares of Lumos Pharma?

The following Wall Street analysts have issued research reports on Lumos Pharma in the last twelve months:
View the latest analyst ratings for LUMO.

What is the current price target for Lumos Pharma?

0 Wall Street analysts have set twelve-month price targets for Lumos Pharma in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Lumos Pharma in the next year.
View the latest price targets for LUMO.

What is the current consensus analyst rating for Lumos Pharma?

Lumos Pharma currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for LUMO.

What other companies compete with Lumos Pharma?

Other companies that are similar to Lumos Pharma include Scilex, Cardiff Oncology, Anixa Biosciences, VistaGen Therapeutics and Cognition Therapeutics. Learn More about companies similar to Lumos Pharma.

How do I contact Lumos Pharma's investor relations team?

Lumos Pharma's physical mailing address is 4200 MARATHON BLVD. SUITE 200, AUSTIN TX, 78756. The company's listed phone number is (512) 215-2630 and its investor relations email address is [email protected]. The official website for Lumos Pharma is www.lumos-pharma.com. Learn More about contacing Lumos Pharma investor relations.